We know that patients with GC best selected for immuno checkpoint are those with a predictive biomarker such as tumor mutational burden-high, expression of PDL-1, microsatellite instability(MSI) or Epstein-Barr virus (EBV) positive tumors, but PM shows PDL1 expression less frequently [24,25]. This evidence concerns the gene CD274 and neoplasm.